Search

Your search keyword '"Barberis, Massimo"' showing total 24 results
Start Over Author "Barberis, Massimo" Publisher mdpi ag
24 results on '"Barberis, Massimo"'

1. Association between Contrast-Enhanced Computed Tomography Radiomic Features, Genomic Alterations and Prognosis in Advanced Lung Adenocarcinoma Patients

Author

Rinaldi, Lisa, primary, Guerini Rocco, Elena, additional, Spitaleri, Gianluca, additional, Raimondi, Sara, additional, Attili, Ilaria, additional, Ranghiero, Alberto, additional, Cammarata, Giulio, additional, Minotti, Marta, additional, Lo Presti, Giuliana, additional, De Piano, Francesca, additional, Bellerba, Federica, additional, Funicelli, Gianluigi, additional, Volpe, Stefania, additional, Mora, Serena, additional, Fodor, Cristiana, additional, Rampinelli, Cristiano, additional, Barberis, Massimo, additional, De Marinis, Filippo, additional, Jereczek-Fossa, Barbara Alicja, additional, Orecchia, Roberto, additional, Rizzo, Stefania, additional, and Botta, Francesca, additional

Published
2023
Full Text
View/download PDF

2. Hereditary Gastric Cancer: Single-Gene or Multigene Panel Testing? A Mono-Institutional Experience

Author

Calvello, Mariarosaria, primary, Marabelli, Monica, additional, Gandini, Sara, additional, Marino, Elena, additional, Bernard, Loris, additional, Dal Molin, Matteo, additional, Di Cola, Giulia, additional, Zanzottera, Cristina, additional, Corso, Giovanni, additional, Fazio, Nicola, additional, Gervaso, Lorenzo, additional, Fumagalli Romario, Uberto, additional, Barberis, Massimo, additional, Guerrieri-Gonzaga, Aliana, additional, Bertario, Lucio, additional, Serrano, Davide, additional, and Bonanni, Bernardo, additional

Published
2023
Full Text
View/download PDF

3. The Genetic and Immunologic Landscape Underlying the Risk of Malignant Progression in Laryngeal Dysplasia

Author

Chu, Francesco, primary, Maffini, Fausto, additional, Lepanto, Daniela, additional, Vacirca, Davide, additional, Taormina, Sergio Vincenzo, additional, De Berardinis, Rita, additional, Gandini, Sara, additional, Vignati, Silvano, additional, Ranghiero, Alberto, additional, Rappa, Alessandra, additional, Chiocca, Susanna, additional, Barberis, Massimo, additional, Tagliabue, Marta, additional, and Ansarin, Mohssen, additional

Published
2023
Full Text
View/download PDF

4. Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer

Author

Venetis, Konstantinos, primary, Pepe, Francesco, additional, Munzone, Elisabetta, additional, Sajjadi, Elham, additional, Russo, Gianluca, additional, Pisapia, Pasquale, additional, Ivanova, Mariia, additional, Bonizzi, Giuseppina, additional, Vacirca, Davide, additional, Rappa, Alessandra, additional, Ranghiero, Alberto, additional, Taormina, Sergio Vincenzo, additional, Viale, Giuseppe, additional, Troncone, Giancarlo, additional, Barberis, Massimo, additional, Guerini-Rocco, Elena, additional, Malapelle, Umberto, additional, and Fusco, Nicola, additional

Published
2022
Full Text
View/download PDF

5. Nodal Merkel Cell Carcinoma with Unknown Primary Site and No Distant Metastasis: A Single-Center Series

Author

Fazio, Nicola, primary, Maisonneuve, Patrick, additional, Spada, Francesca, additional, Gervaso, Lorenzo, additional, Cella, Chiara Alessandra, additional, Pozzari, Marta, additional, Zerini, Dario, additional, Pisa, Eleonora, additional, Fumagalli, Caterina, additional, Barberis, Massimo, additional, Laffi, Alice, additional, Grana C., Chiara Maria, additional, Orsolini, Gianmarco, additional, Prestianni, Pierpaolo, additional, Bonomo, Guido, additional, Funicelli, Luigi, additional, Bertani, Emilio, additional, Queirolo, Paola, additional, Ravizza, Davide, additional, Rubino, Manila, additional, Tosti, Giulio, additional, and Pennacchioli, Elisabetta, additional

Published
2022
Full Text
View/download PDF

6. Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes

Author

Cella, Chiara Alessandra, primary, Spada, Francesca, additional, Berruti, Alfredo, additional, Bertolini, Francesco, additional, Mancuso, Patrizia, additional, Barberis, Massimo, additional, Pisa, Eleonora, additional, Rubino, Manila, additional, Gervaso, Lorenzo, additional, Laffi, Alice, additional, Pellicori, Stefania, additional, Radice, Davide, additional, Zorzino, Laura, additional, Calleri, Angelica, additional, Funicelli, Luigi, additional, Petralia, Giuseppe, additional, and Fazio, Nicola, additional

Published
2022
Full Text
View/download PDF

7. Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles

Author

Sajjadi, Elham, primary, Venetis, Konstantinos, additional, Noale, Marianna, additional, Azim, Hatem A., additional, Blundo, Concetta, additional, Bonizzi, Giuseppina, additional, Di Loreto, Eugenia, additional, Scarfone, Giovanna, additional, Ferrero, Stefano, additional, Maggi, Stefania, additional, Barberis, Massimo, additional, Veronesi, Paolo, additional, Galimberti, Viviana E., additional, Viale, Giuseppe, additional, Fusco, Nicola, additional, Peccatori, Fedro A., additional, and Guerini-Rocco, Elena, additional

Published
2022
Full Text
View/download PDF

9. Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future—Five-Years’ Single-Institution Experience of 762 Consecutive Patients

Author

Fumagalli, Caterina, primary, Betella, Ilaria, additional, Rappa, Alessandra, additional, di Giminiani, Maria, additional, Gaiano, Michela, additional, De Vitis, Luigi Antonio, additional, Zambetti, Benedetta, additional, Vacirca, Davide, additional, Multinu, Francesco, additional, Venetis, Konstantinos, additional, Colombo, Nicoletta, additional, Barberis, Massimo, additional, and Guerini Rocco, Elena, additional

Published
2022
Full Text
View/download PDF

11. A Retrospective Analysis of the Correlation between Functional Imaging and Clinical Outcomes in Grade 3 Neuroendocrine Tumors (NETs G3)

Author

Laffi, Alice, primary, Colandrea, Marzia, additional, Buonsanti, Giuseppe, additional, Frassoni, Samuele, additional, Bagnardi, Vincenzo, additional, Spada, Francesca, additional, Pisa, Eleonora, additional, Barberis, Massimo, additional, Rubino, Manila, additional, Grana, Chiara Maria, additional, Ceci, Francesco, additional, and Fazio, Nicola, additional

Published
2021
Full Text
View/download PDF

12. Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms

Author

Bulloni, Matteo, primary, Sandrini, Giada, additional, Stacchiotti, Irene, additional, Barberis, Massimo, additional, Calabrese, Fiorella, additional, Carvalho, Lina, additional, Fontanini, Gabriella, additional, Alì, Greta, additional, Fortarezza, Francesco, additional, Hofman, Paul, additional, Hofman, Veronique, additional, Kern, Izidor, additional, Maiorano, Eugenio, additional, Maragliano, Roberta, additional, Marchiori, Deborah, additional, Metovic, Jasna, additional, Papotti, Mauro, additional, Pezzuto, Federica, additional, Pisa, Eleonora, additional, Remmelink, Myriam, additional, Serio, Gabriella, additional, Marzullo, Andrea, additional, Trabucco, Senia Maria Rosaria, additional, Pennella, Antonio, additional, De Palma, Angela, additional, Marulli, Giuseppe, additional, Fassina, Ambrogio, additional, Maffeis, Valeria, additional, Nesi, Gabriella, additional, Naheed, Salma, additional, Rea, Federico, additional, Ottensmeier, Christian H., additional, Sessa, Fausto, additional, Uccella, Silvia, additional, Pelosi, Giuseppe, additional, and Pattini, Linda, additional

Published
2021
Full Text
View/download PDF

16. Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations

Author

Passaro, Antonio, primary, Attili, Ilaria, additional, Rappa, Alessandra, additional, Vacirca, Davide, additional, Ranghiero, Alberto, additional, Fumagalli, Caterina, additional, Guarize, Juliana, additional, Spaggiari, Lorenzo, additional, de Marinis, Filippo, additional, Barberis, Massimo, additional, and Guerini-Rocco, Elena, additional

Published
2021
Full Text
View/download PDF

17. Emergency Lung Transplantation after COVID-19: Immunopathological Insights on Two Affected Patients

Author

Croci, Giorgio A., primary, Vaira, Valentina, additional, Trabattoni, Daria, additional, Biasin, Mara, additional, Valenti, Luca, additional, Baselli, Guido, additional, Barberis, Massimo, additional, Guerini Rocco, Elena, additional, Gregato, Giuliana, additional, Scandroglio, Mara, additional, Fominskiy, Evgeny, additional, Palleschi, Alessandro, additional, Rosso, Lorenzo, additional, Nosotti, Mario, additional, Clerici, Mario, additional, and Ferrero, Stefano, additional

Published
2021
Full Text
View/download PDF

19. Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record

Author

Pagni, Fabio, primary, Malapelle, Umberto, additional, Doglioni, Claudio, additional, Fontanini, Gabriella, additional, Fraggetta, Filippo, additional, Graziano, Paolo, additional, Marchetti, Antonio, additional, Guerini Rocco, Elena, additional, Pisapia, Pasquale, additional, Vigliar, Elena V., additional, Buttitta, Fiamma, additional, Jaconi, Marta, additional, Fusco, Nicola, additional, Barberis, Massimo, additional, and Troncone, Giancarlo, additional

Published
2020
Full Text
View/download PDF

20. Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy

Author

Fumagalli, Caterina, primary, Tomao, Federica, additional, Betella, Ilaria, additional, Rappa, Alessandra, additional, Calvello, Mariarosaria, additional, Bonanni, Bernardo, additional, Bernard, Loris, additional, Peccatori, Fedro, additional, Colombo, Nicoletta, additional, Viale, Giuseppe, additional, Barberis, Massimo, additional, and Guerini-Rocco, Elena, additional

Published
2019
Full Text
View/download PDF

22. Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer

Author

Konstantinos Venetis, Francesco Pepe, Elisabetta Munzone, Elham Sajjadi, Gianluca Russo, Pasquale Pisapia, Mariia Ivanova, Giuseppina Bonizzi, Davide Vacirca, Alessandra Rappa, Alberto Ranghiero, Sergio Vincenzo Taormina, Giuseppe Viale, Giancarlo Troncone, Massimo Barberis, Elena Guerini-Rocco, Umberto Malapelle, Nicola Fusco, Venetis, Konstantino, Pepe, Francesco, Munzone, Elisabetta, Sajjadi, Elham, Russo, Gianluca, Pisapia, Pasquale, Ivanova, Mariia, Bonizzi, Giuseppina, Vacirca, Davide, Rappa, Alessandra, Ranghiero, Alberto, Vincenzo Taormina, Sergio, Viale, Giuseppe, Troncone, Giancarlo, Barberis, Massimo, Guerini-Rocco, Elena, Malapelle, Umberto, and Fusco, Nicola

Subjects
General Medicine, breast cancer, biomarkers, PIK3CA, NGS, RT-PCR
Abstract

Somatic mutations in PIK3CA are present in ~40% breast cancers (BC); their detection in hormone receptor (HR)+/HER2− tumors allows for selecting patients with advanced disease eligible for PIK3CA targeting with alpelisib. The choice of what type of PIK3CA testing approach to adopt and which tissue sample to analyze is a new task in breast pathology. In this methodological study, we sought to assess the performance of next-generation sequencing (NGS) and RT-PCR for PIK3CA testing on archival formalin-fixed paraffin-embedded (FFPE) primary tumors and corresponding metastases. Sixteen HR+/HER2− BC with known PIK3CA-mutated status (ex. 7, 9, and 20) on metastatic samples by means of amplicon-based targeted NGS were selected, and n = 13 of these samples were re-tested with a commercially available CE-IVD RT-PCR assay. All available primary tumors (n = 8) were tested with both methods. NGS detected mutations in all samples, while RT-PCR in n = 2 sample-pairs and overall, in n = 5/8 (62.5%) primary tumors and 7/13 (53.8%) metastases (κ = 0.09; 95% CI, −0.69–0.87). Slight agreement (κ = 0; 95% CI, −0.59–0.59) was observed between NGS and RT-PCR, with the former being generally more sensitive in cases with low DNA quality and quantity. Post hoc visual inspection of the RT-PCR data increased the concordance to 76.9%. Targeted NGS offers reliable and robust PIK3CA testing on both tumor and metastasis FFPE samples; the accuracy of RT-PCR depends on the DNA quantity and quality. In HR+/HER2− BC, both the selection of the PIK3CA testing strategy of FFPE tissues and which sample to analyze should consider several technical parameters and should be tailored for each case.

Published
2022

23. BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories

Author

Ettore Capoluongo, Nicla La Verde, Massimo Barberis, Maria Angela Bella, Fiamma Buttitta, Paola Carrera, Nicoletta Colombo, Laura Cortesi, Maurizio Genuardi, Massimo Gion, Valentina Guarneri, Domenica Lorusso, Antonio Marchetti, Paolo Marchetti, Nicola Normanno, Barbara Pasini, Matilde Pensabene, Sandro Pignata, Paolo Radice, Enrico Ricevuto, Anna Sapino, Pierosandro Tagliaferri, Pierfrancesco Tassone, Chiara Trevisiol, Mauro Truini, Liliana Varesco, Antonio Russo, Stefania Gori, Capoluongo, Ettore, La Verde, Nicla, Barberis, Massimo, Bella, Maria Angela, Buttitta, Fiamma, Carrera, Paola, Colombo, Nicoletta, Cortesi, Laura, Gion, Massimo, Guarneri, Valentina, Lorusso, Domenica, Marchetti, Antonio, Marchetti, Paolo, Normanno, Nicola, Pasini, Barbara, Pensabene, Matilde, Pignata, Sandro, Radice, Paolo, Ricevuto, Enrico, Sapino, Anna, Tagliaferri, Pierosandro, Tassone, Pierfrancesco, Trevisiol, Chiara, Truini, Mauro, Varesco, Liliana, Russo, Antonio, Gori, Stefania, Capoluongo, E, Verde, N, Barberis, M, Bella, M, Buttitta, F, Carrera, P, Colombo, N, Cortesi, L, Gion, M, Guarneri, V, Lorusso, D, Marchetti, A, Marchetti, P, Normanno, N, Pasini, B, Pensabene, M, Pignata, S, Radice, P, Ricevuto, E, Sapino, A, Tagliaferri, P, Tassone, P, Trevisiol, C, Truini, M, Varesco, L, Russo, A, and Gori, S

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Genetic counseling, Clinical Biochemistry, Somatic BRCA, Multidisciplinary team, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, PARP-1i, medicine, brca1/2 assays, lcsh:R5-920, business.industry, BRCA1/2 assays, BRCA1/2 assay, Ovary cancer, Test (assessment), Laboratory test, 030104 developmental biology, Multicenter study, 030220 oncology & carcinogenesis, Cancer genetics, Pretest posttest, NGS, lcsh:Medicine (General), business
Abstract

In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for BRCA1/2. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing BRCA1/2 germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput.

Published
2019

24. BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.

Author

Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, and Gori S

Abstract

In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for BRCA1/2 . The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing BRCA1/2 germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput., Competing Interests: The authors declare no conflict of interest.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results